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Results and discussion
C28 induces mitotic arrest in breast cancer cells
Human lemur tyrosine kinase 3 (LMTK3) is a dual spe-
cificity kinase, whose oncogenic role has been well-
established in different tumour types, supporting its
potential as a therapeutic target [1]. Recently, using ro-
bust in vitro and cell-based screening- and selectivity-
assays combined with biophysical analyses, we identified
a selective small molecule ATP-competitive LMTK3
inhibitor (C28; Fig. 1a) that acts by degrading LMTK3
via the ubiquitin-proteasome pathway. C28 demon-
strated effective anticancer effects in a variety of cancer
cell lines and in in vivo breast cancer (BC) mouse
models [2]. This potent, selective and cell-permeable
inhibitor represents an effective tool to investigate and
decipher the signalling pathways in which LMTK3 is
implicated and progress with our translational research
work.
In order to decipher the mechanism of action of C28,
we initially performed flow cytometry (FACS) analysis
and revealed that treatment with C28 leads to G2/M
phase arrest of BC cells as well as MCF12A, a non-
transformed breast cell line (Fig. 1b). This result was
confirmed by evaluating the increased mitotic index (Fig.
1c) and by the upregulation of the mitotic marker
phospho-histone H3 (Ser10) (Fig. 1d). As previously re-
ported [2], prolonged exposure to C28 induced apoptosis
of BC cells but had a low % of cell death (< 5%) in
MCF12A, suggesting that non-transformed breast epi-
thelial cells evade death while working on recuperating
from cell cycle arrest (Fig. 1b). Similarly, silencing of
LMTK3 led to an increase in phospho-histone H3
(Ser10) levels, suggesting a potential role of LMTK3 in
G2/M transition (Fig. 1e), although no evident effects on
cell cycle distribution were observed during the 72 h-
period of siRNA treatment (data not shown), in accord-
ance with previously published data [1].
C28 interferes with tubulin polymerization and mitotic
spindle organization
Bearing in mind the effects of C28 on cell cycle arrest
and the induction of cell death, we investigated whether
C28 impacts microtubule dynamics, which can in turn
disturb the organization of the cytoskeleton and affect
cell division [3]. Immunofluorescence of cells at the
metaphase revealed that C28-treated cells present
disrupted microtubule distribution and mitotic defects,
including abnormal microtubule spindle organization
and an altered chromosome condensation pattern
(Supplementary Fig. S1a).
Following, the effect of C28 on microtubule stability was
confirmed using a cell-based microtubule polymerization
assay, where we observed a dose dependent decrease of
the insoluble polymerized tubulin fraction. (Fig. 1f). Inter-
estingly, the magnitude of C28 effects appeared to be cell-
line dependent, suggesting the existence of different
proteins and signalling pathways that may be implicated
and affect this phenotype.
Considering the role of kinase inhibitors on microtu-
bules [4, 5], we investigated the possibility that C28 is a
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Fig. 1 C28 induces the accumulation of mitotic cells and disrupts microtubule dynamics. a Chemical structure of C28. b Synchronized MCF7, T47D, MDA-MB-
231 and MCF12A cell lines were analysed by flow cytometry (FACS) following treatment with increasing concentrations (0, 1, 5 and 10 μM) of C28 for 48 h.
Percentages of cells in G0/G1, S and G2/M phase are indicated. Results are expressed as mean± SEM. The experiment was performed two times. c MCF7,
T47D, MDA-MB-231 and MCF12A cell lines were treated with increasing concentrations (0, 1, 5 and 10 μM) of C28 for 48 h and mitotic cells were counted.
The mitotic index is represented as the percentage of mitotic cells over the total number of cells counted. The experiment was performed two times. ANOVA
statistic test was performed using Prism 8 software. Results are expressed as mean± SEM; * P < 0.05, ** P <0.01. dWestern blotting analysis of the phospho-
histone H3 (Ser10) mitotic marker in MCF7, T47D, MDA-MB-231, MCF12A cell lines following treatment with increasing concentrations of C28 for 48 h. GADPH
was used as loading control. Values represent the average of three experiments. eWestern blotting analysis of the phospho-histone H3 (Ser10) mitotic marker
in MCF7, T47D, MDA-MB-231 cell lines following siRNA silencing of LMTK3 for 72 h. GADPH was used as loading control. Values represent the average of three
experiments. f MCF7, T47D and MDA-MB-231 cell lines were treated with increasing concentrations (0, 1, 5 and 10μM) of C28 for 48 h. Cells were centrifuged
to separate the insoluble (polymerized) and soluble (un-polymerized) tubulin, and fractions were analysed by western blotting. Colchicine (50 nM) or paclitaxel
(50 nM) served as positive or negative control respectively. Values represent the ratio between the insoluble and soluble fractions and are the average of three
experiments. g In vitro polymerization of bovine purified tubulin following incubation with increasing concentrations (0, 1, 5, 10 and 20 μM) of C28.
Nocodazole (10μM) or paclitaxel (10μM) served as positive or negative controls respectively. The optical density (OD) was measured at 350 nm. h Molecular
model of C28 bound to the colchicine site of tubulin in comparison with the X-ray crystal structure of tubulin complex with nocodazole (PDB ID: 5ca1) (29).
The subunits α and β of tubulin are illustrated as purple and blue ribbons, respectively. Nocodazole (NZO) is shown with green C atoms, whereas C28 with
orange C; all other atoms are coloured blue for N, red for O and pink for F. Potential hydrogen-bonding interactions between the ligands and key residues of
tubulin are indicated with dashed lines. i Dose-dependent quenching of the intrinsic fluorescence of purified tubulin upon C28 binding. Fluorescence spectra
of free tubulin 2 μΜ in PIPES buffer pH 6.9 (black line) and with increasing concentrations of C28 as indicated in the legend. Fluorescence was monitored at
25 °C in the range of 310 to 420 nm by excitation at 290 nm. Inset, is the change in the fluorescence intensity of tubulin heterodimers (ΔF) as a function of
C28 concentration, from which the apparent dissociation constant (Kd) was estimated to be 73 ± 15 μΜ by fitting to the equation described in the methods
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direct tubulin-targeting agent by employing an in vitro
tubulin polymerization assay. The effects on the assem-
bly of purified porcine tubulin were evaluated by
measuring the absorbance at 350 nm at 37 °C, using pac-
litaxel and nocodazole as comparative agents. As ex-
pected, paclitaxel promoted tubulin polymerization,
while nocodazole inhibited it, as demonstrated by the in-
creased fluorescence intensity (compared to the control)
in the former and decrease in the latter. Contrariwise,
incubation of tubulin with increasing concentrations of
C28 at different time points had no effects on tubulin
polymerization (Fig. 1g).
To examine whether C28 binds tubulin at the atomic
level, we performed docking calculations of C28 in com-
parison with nocodazole, a reversible inhibitor of micro-
tubule polymerization and a high-affinity ligand for the
cancer-related kinases ABL, BRAF, c-KIT and MEK [6].
Our docking results using the high-resolution X-ray crys-
tal structure of tubulin complex with nocodazole (PDB
ID: 5ca1) revealed that C28 can be accommodated at the
colchicine binding site of the β-subunit of tubulin (Fig.
1h). In particular, C28 is predicted to interact with both α
and β subunits of the curved (unassembled) tubulin, but
not as deep inside the β subunit as nocodazole. Compared
with nocodazole that has been shown to bind β-tubulin
via hydrogen-bonding interactions with Asn165 and
Glu198 (Fig. 1h), C28 displayed a potential hydrogen
bonding interaction with Glu198 and a halogen bond with
Thr179 of the α-subunit. The free energy of binding to
tubulin was estimated to be − 9.1 kcal/mol for C28 and −
10.4 kcal/mol for nocodazole, suggesting an approximately
10-fold lower affinity of C28 for tubulin.
The binding affinity of C28 to tubulin was further exam-
ined in vitro by monitoring the intrinsic tryptophan fluor-
escence of tubulin, a widely used method to determine the
binding affinity of drugs for tubulin heterodimers [7]. In-
cubation of purified porcine tubulin with C28 revealed a
concentration-dependent quenching of the fluorescence at
310–420 nm and the changes in the fluorescence intensity
were fitted to a binding isotherm as previously described
[7] (Fig. 1i). The apparent dissociation constant (Kd) of
C28 to purified tubulin heterodimers was estimated to be
73 ± 15 μΜ. For comparison, the binding affinity of noco-
dazole for purified tubulin was measured with apparent
dissociation constants between 0.29 and 1.54 μΜ, depend-
ing on the specific tubulin isotype used. This result is in
agreement with the lack of any observable effect on tubu-
lin polymerization upon treatment with C28 concentra-
tions of 1–20 μΜ in vitro (Fig. 1g).
Taken together, although C28 can potentially bind tubu-
lin, its relatively low binding affinity to purified tubulin
dimer and the lack of any observable effect on tubulin
polymerization suggest that C28 does not confer its effects
by direct inhibition of tubulin polymerization. Instead our
data imply that C28 modulates LMTK3-regulated path-
ways linked to microtubule assembly, a result that can
partly explain the previously observed universal cytotoxic
effects of C28 on the NCI-60 cancer cell line panel [2].
Pharmacological or genetic inhibition of LMTK3
downregulates NUSAP1 microtubule-associated protein
In an attempt to decipher the signalling pathways via which
C28 confers its effects on microtubules assembly, we used a
tandem mass tagging (TMT) quantitative proteomic ap-
proach and uncovered the C28-mediated global proteomic
alterations in BC cells (Fig. 2a). Following quantile
normalization of TMT label intensities for each channel,
2852 distinguishable and unambiguous proteins were iden-
tified with a minimum of one unique peptide with a false
discovery rate (FDR) of 1% (Supplementary Table S1). As
anticipated, LMTK3 was amongst the downregulated pro-
teins following treatment with C28 (Fig. 2a).
Interestingly, amongst the most significant C28-
modulated hits was NUSAP1 (P < 0.05 and Log2 fold
change of ≥|1.25|), a microtubule associated protein par-
ticipating in mitotic spindle organization [8, 9], whose role
has been closely associated with tumour progression, che-
moresistance, and poor prognosis in many tumours in-
cluding BC [10, 11]. The effects of C28 on NUSAP1 were
validated in additional BC cell lines (Fig. 2b). In addition,
to confirm the involvement of NUSAP1 in the C28-
mediated effect on microtubule stability and cell cycle ar-
rest, we investigated the levels of cyclin-dependent kinase
1 (CDK1), a previously described NUSAP1-regulated
protein [12], and phospho-βIII tubulin (S172). This latter
phosphorylation is catalysed by CDK1 and has been
shown to influence microtubule dynamics by affecting
their polymerization [13, 14] (Fig. 2b) To corroborate that
the observed effects are due to the selective C28-mediated
LMTK3 inhibition, we silenced LMTK3 (siRNA) and saw
a downregulation of NUSAP1, CDK1, and phospho-βIII
tubulin (S172) (Fig. 2c). To further establish that this was
an LMTK3/NUSAP1-mediated effect, we restored
LMTK3 levels following C28 treatment and detected a
rescue of NUSAP1 levels (Fig. 2d). In addition, a recovery
of CDK1, phospho-βIII tubulin (S172) and phospho-
histone H3 (Ser10) levels were observed after restoring
NUSAP1 following C28 treatment (Fig. 2e). Altogether,
these data confirm that C28 affects microtubule dynamics
via an LMTK3 and NUSAP1-regulated pathway. More-
over, following immunoprecipitation experiments, an
endogenous interaction of LMTK3 with NUSAP1 was dis-
covered (Fig. 2f), suggesting, as previously reported [15],
that LMTK3 may function as a scaffold protein able to
interact with and stabilize NUSAP1.
Finally, we investigated the association between mRNA
levels of LMTK3 and NUSAP1 with survival. Our ana-
lysis revealed that high expression of LMTK3 and
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Fig. 2 (See legend on next page.)
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NUSAP1 correlates with shorter overall survival (Fig. 2g)
and disease-free survival (Fig. 2h), indicating a plausible
cooperation of LMTK3 and NUSAP1 in BC progression.
Conclusions
In the present study, we further demonstrated that C28
exerts its antitumor functions by degrading LMTK3 [2],
which leads to a NUSAP1-mediated microtubule instabil-
ity with subsequent cell-cycle arrest and cell death. More-
over, downregulation of NUSAP1-downstream proteins
involved in cell cycle regulation and microtubule stability
(CDK1 and phospho-βIII tubulin), after pharmacological
and genetic LMTK3 inhibition, support this hypothesis
(Supplementary Fig. S1b). Although we cannot rule out
the possibility that the anticancer activity of C28 is also
due to off-target effects, our LMTK3 and NUSAP1 recov-
ery studies support that the observed results on micro-
tubule stability are predominantly mediated via LMTK3
inhibition. In addition, the identification of NUSAP1 as a
new interacting partner of LMTK3 suggests a direct inter-
play between LMTK3 and NUSAP1 pathways in the regu-
lation of microtubule stability and validates the LMTK3
scaffolding properties, which can eventually contribute to
tumorigenesis by enhancing signalling complexity [15].
Furthermore, our clinical data imply an association be-
tween NUSAP1 and LMTK3 in BC progression as shown
by their unfavourable prognosis.
Combined, our findings propose that the pre-clinical
therapeutic advantage of C28 stems from its effect on the
LMTK3-targeted pathways linked to microtubule
organization, acting differently from the established role
of chemotherapeutic agents including vinca-alkaloids [16],
taxanes [16] or eribulin [17], which confer their cytotox-
icity via their interactions with tubulin causing disruption
of microtubule function. The clinical use of microtubule-
targeting drugs as anticancer drugs is well-established
[18], while the ability of standard microtubule agents (i.e.
nocodazole) to modulate the activities of certain kinases
has also been reported [6]. Taken together, the develop-
ment and design of multifunctional inhibitors can provide
new, promising approaches for cancer treatment.
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Fig. 2 C28 decreases NUSAP1 protein levels. a Volcano plot of differentially expressed proteins following treatment with C28 in MCF7 cells stably
overexpressing LMTK3. The plot illustrates the -Log10 P-value vs. the Log2 fold change of protein abundance in the presence of C28. The
significance threshold (P = 0.05) is represented by a horizontal line. The two vertical lines (Log2 fold change of ≥1.5 and≤ − 1.5) represent the
cut-off values of interest. b Western blotting analysis of NUSAP1, CDK1, phospho-βIII tubulin (S172) and β tubulin in MCF7, T47D and MDA-MB-
231 cell lines following treatment with increasing concentrations (0, 1, 5 and 10 μM) of C28 for 48 h. GADPH was used as loading control. Values
represent the average of two experiments. c Western blotting of NUSAP1, CDK1, phospho-βIII tubulin (S172) and β tubulin in MCF7, T47D and
MDA-MB-231 cell lines following inhibition (siRNA) of LMTK3. GADPH was used as loading control. Values represent the average of two
experiments. d Western blotting showing the effects of LMTK3 overexpression, using a pCMV6-LMTK3 plasmid, on NUSAP1 protein levels in
MCF7, T47D and MDA-MB-231 cell lines following 48 h pre-treatment with 10 μM C28. GADPH was used as loading control. Values represent the
average of two experiments. e Western blotting analysis showing the effects of NUSAP1 overexpression, using a pCMV6-NUSAP1 plasmid, on
CDK1, phospho-βIII tubulin (S172) and phospho-histone H3 (Ser10) in MCF7, T47D and MDA-MB-231 cell lines following 48 h pre-treatment with
10 μM C28. GADPH was used as loading control. Values represent the average of two experiments. f LMTK3 or NUSAP1 were immunoprecipitated
from MCF7 cells stably overexpressing LMTK3, and the complexes were immunoblotted for LMTK3 and NUSAP1. Western blots for the respective
proteins in whole cell lysates (input) were also performed. g Kaplan-Meier plots (http://kmplot.com/) demonstrating the association of the mean
expression of LMTK3 and NUSAP1 with overall survival in 626 BC patients. HR, hazard ratio. h Kaplan-Meier plots (http://kmplot.com/)
demonstrating the association of the mean expression of LMTK3 and NUSAP1 with disease free survival in 1764 BC patients
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